Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension.
暂无分享,去创建一个
Jason B. Giles | R. Kittles | H. Tiwari | A. Sweatt | J. Karnes | R. Benza | J. Yuan | Haiyang Tang | Tae‐Hwi Schwantes‐An | R. Vanderpool | W. Nichols | V. A. de Jesus Perez | A. Desai | Joe G. N. Garcia | H. Wiener | A. Chaturvedi | R. Zamanian | M. Hosseini | M. Pauciulo | Vineet Nair | K. Lutz | A. Coleman | F. Rischard | J. Feldman | H. Steiner | Amit Arora | B. Natarajan | Ken Batai | Jeffrey Yu
[1] R. Benza,et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. , 2019, Chest.
[2] B. Dean,et al. Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms , 2019, Annals of the American Thoracic Society.
[3] M. Humbert,et al. Prostacyclin for pulmonary arterial hypertension. , 2019, The Cochrane database of systematic reviews.
[4] Lisa J. Martin,et al. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis , 2018, bioRxiv.
[5] Andrew B. Conley,et al. Genetic ancestry, admixture and health determinants in Latin America , 2018, BMC Genomics.
[6] Henning Gall,et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension , 2018, Nature Communications.
[7] V. Rowe,et al. Controversies and evidence for cardiovascular disease in the diverse Hispanic population. , 2017, Journal of vascular surgery.
[8] Sarah K. Medrek,et al. Ethnicity in Pulmonary Arterial Hypertension: Possibilities for Novel Phenotypes in the Age of Personalized Medicine , 2017, Chest.
[9] J. Paulus,et al. Racial and ethnic differences in pulmonary arterial hypertension , 2017, Pulmonary circulation.
[10] M. Humbert,et al. Epidemiology and treatment of pulmonary arterial hypertension , 2017, Nature Reviews Cardiology.
[11] O. Sitbon,et al. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience , 2017, European Respiratory Review.
[12] H. Shimoura,et al. Right ventricular relative wall thickness as a predictor of outcomes and of right ventricular reverse remodeling for patients with pulmonary hypertension , 2017, The International Journal of Cardiovascular Imaging.
[13] S. Archer,et al. Trends and Outcomes of Pulmonary Arterial Hypertension-Related Hospitalizations in the United States: Analysis of the Nationwide Inpatient Sample Database From 2001 Through 2012. , 2016, JAMA cardiology.
[14] Stephen Kaptoge,et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis , 2016, The Lancet. Respiratory medicine.
[15] A. Torbicki,et al. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.
[16] Carl D. Langefeld,et al. Genomic Insights into the Ancestry and Demographic History of South America , 2015, PLoS genetics.
[17] R. Benza,et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.
[18] C. Sabatti,et al. Characterizing Race/Ethnicity and Genetic Ancestry for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort , 2015, Genetics.
[19] R. Safford,et al. Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. , 2015, Chest.
[20] M. Hoeper,et al. The changing landscape of pulmonary arterial hypertension and implications for patient care , 2014, European Respiratory Review.
[21] F. Lopez‐Jimenez,et al. The Hispanic paradox in cardiovascular disease and total mortality. , 2014, Progress in cardiovascular diseases.
[22] E. Bergot,et al. Increase of pulmonary artery wedge pressure above 15 mm Hg in patients with pre-capillary pulmonary hypertension , 2014 .
[23] D. Balding,et al. Admixture in Latin America: Geographic Structure, Phenotypic Diversity and Self-Perception of Ancestry Based on 7,342 Individuals , 2014, PLoS genetics.
[24] R. Damico,et al. Severity of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension in African Americans , 2014, Medicine.
[25] Mary G. George,et al. Pulmonary Hypertension Surveillance , 2014, Chest.
[26] W. Chung,et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension , 2013, Nature Genetics.
[27] S. Archer,et al. Evolving epidemiology of pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.
[28] Christopher R. Gignoux,et al. Development of a Panel of Genome-Wide Ancestry Informative Markers to Study Admixture Throughout the Americas , 2012, PLoS genetics.
[29] A. Torbicki,et al. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. , 2012, Pulmonary pharmacology & therapeutics.
[30] H. Palevsky,et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. , 2012, Chest.
[31] R. Kronmal,et al. Sex and Race Differences in Right Ventricular Structure and Function: The Multi-Ethnic Study of Atherosclerosis–Right Ventricle Study , 2011, Circulation.
[32] Sindhu R. Johnson,et al. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. , 2010, Respiratory medicine.
[33] D. Altshuler,et al. A map of human genome variation from population-scale sequencing , 2010, Nature.
[34] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[35] S. Ghio,et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. , 2010, International journal of cardiology.
[36] T. Fleming,et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. , 2008, Chest.
[37] M. Humbert,et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. , 2008, American journal of respiratory and critical care medicine.
[38] J. Bronzwaer,et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. , 2007, European heart journal.
[39] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[40] J. Kere,et al. BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension , 2005, Human mutation.
[41] J. Loyd,et al. Primary pulmonary hypertension , 2003, The Lancet.
[42] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[43] G. Koch,et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.
[44] P. Donnelly,et al. Inference of population structure using multilocus genotype data. , 2000, Genetics.
[45] D. Lilienfeld,et al. Mortality from primary pulmonary hypertension in the United States, 1979-1996. , 2000, Chest.
[46] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.